Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open follow-up study of mannan-conjugated birch pollen allergoid 10,000 mTU/mL in T502-SIT-020 participants
2020-004126-32Phase 2Completed
- Sponsor
- Inmunotek
- Start
- Sep 2020
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of birch pollen allergen extract in birch pollen allergy and allergic rhinoconjunctivitis (ARC), sponsored by Inmunotek. Primary endpoint: Clinical impact on symptoms and medication use during April 2021 birch pollen season. Started Sep 2020; status: completed.
02
Drugs
birch pollen allergen extract
03
Conditions
birch pollen allergyallergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2020-004126-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004126-32.